Great Point Partners Invests in Tergus Pharma

MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader

July 8, 2024

Pharmaceuticals

MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

Great Point Partners Makes Growth Investment in Ephicacy Consulting Group

July 21, 2022

Healthcare Services

Great Point Partners completed a growth investment in Ephicacy Consulting Group, a biometrics contract research organization (CRO) that provides statistical programming, data management, and real-world evidence analytics. The minority growth capital partnership will support Ephicacy's accelerated growth across its operations in the United States, Canada, and India and expand its clinical analytics capabilities.

Great Point Partners Completes Growth Recapitalization of Velentium

September 29, 2021

Medical Devices

Great Point Partners completed a growth recapitalization of Houston-based Velentium, a professional engineering and contract medical device manufacturer. The investment will fund Velentium's expansion initiatives — including tuck-in acquisitions and enhanced engineering and manufacturing capabilities — while preserving the company's quality and culture.

Ampersand Capital Partners Acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launches Gannet BioChem

December 2, 2024

Biotechnology

Ampersand Capital Partners has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business and launched the new Ampersand portfolio company, Gannet BioChem, operating from a 124,000 sq. ft. FDA‑inspected facility in Huntsville, Alabama. The transaction represents a divestiture by Nektar and creates an independent specialty CDMO focused on development, scaling, and GMP production of polyethylene glycol (PEG) reagents for clinical and commercial biopharmaceutical customers.